NeuroMetrix Inc. (NASDAQ:NURO) went up by 2.57% from its latest closing price compared to the recent 1-year high of $38.75. The company’s stock price has collected -2.00% of loss in the last five trading sessions. Press Release reported on 08/27/21 that Thinking about buying stock in Support.com, Neurometrix, Exela Technologies, Takung Art, or Acasti Pharma?
Is It Worth Investing in NeuroMetrix Inc. (NASDAQ :NURO) Right Now?
Plus, the 36-month beta value for NURO is at 3.09. Opinions of the stock are interesting as 1 analysts out of 1 who provided ratings for NeuroMetrix Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 0 rated it as “hold,” and 0 as “sell.”
The average price from analysts is $50.00. NURO currently public float of 3.09M and currently shorts hold a 36.88% ratio of that float. Today, the average trading volume of NURO was 9.87M shares.
NURO’s Market Performance
NURO stocks went down by -2.00% for the week, with a monthly drop of -11.72% and a quarterly performance of 216.76%, while its annual performance rate touched 585.99%. The volatility ratio for the week stands at 9.09% while the volatility levels for the past 30 days are set at 13.79% for NeuroMetrix Inc.. The simple moving average for the period of the last 20 days is -6.83% for NURO stocks with a simple moving average of 101.46% for the last 200 days.
Analysts’ Opinion of NURO
Many brokerage firms have already submitted their reports for NURO stocks, with H.C. Wainwright repeating the rating for NURO by listing it as a “Buy.” The predicted price for NURO in the upcoming period, according to H.C. Wainwright is $3 based on the research report published on October 20th of the previous year 2017.
Rodman & Renshaw, on the other hand, stated in their research note that they expect to see NURO reach a price target of $4.50. The rating they have provided for NURO stocks is “Buy” according to the report published on June 28th, 2016.
Maxim Group gave a rating of “Buy” to NURO, setting the target price at $2 in the report published on September 11th of the previous year.
NURO Trading at -4.98% from the 50-Day Moving Average
After a stumble in the market that brought NURO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.21% of loss for the given period.
Volatility was left at 13.79%, however, over the last 30 days, the volatility rate increased by 9.09%, as shares sank -16.06% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +208.60% upper at present.
During the last 5 trading sessions, NURO fell by -2.00%, which changed the moving average for the period of 200-days by +436.46% in comparison to the 20-day moving average, which settled at $11.46. In addition, NeuroMetrix Inc. saw 240.82% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at NURO starting from HIGGINS THOMAS T, who sale 50,000 shares at the price of $10.55 back on Aug 25. After this action, HIGGINS THOMAS T now owns 23,659 shares of NeuroMetrix Inc., valued at $527,500 using the latest closing price.
HIGGINS THOMAS T, the Senior Vice President, CFO of NeuroMetrix Inc., sale 20,000 shares at $13.56 during a trade that took place back on Aug 12, which means that HIGGINS THOMAS T is holding 23,659 shares at $271,200 based on the most recent closing price.
Stock Fundamentals for NURO
Current profitability levels for the company are sitting at:
- -18.23 for the present operating margin
- +71.15 for the gross margin
The net margin for NeuroMetrix Inc. stands at -28.36. The total capital return value is set at -26.00, while invested capital returns managed to touch -45.70. Equity return is now at value -19.00, with -13.50 for asset returns.
Based on NeuroMetrix Inc. (NURO), the company’s capital structure generated 20.22 points at debt to equity in total, while total debt to capital is 16.82. Total debt to assets is 13.27, with long-term debt to equity ratio resting at 8.79. Finally, the long-term debt to capital ratio is 7.31.
When we switch over and look at the enterprise to sales, we see a ratio of 0.73, with the company’s debt to enterprise value settled at 0.20. The receivables turnover for the company is 17.95 and the total asset turnover is 0.99. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.10.